Pacgen, a developer of therapeutic drug candidates, has appointed Ming Liu as new chief executive officer (CEO) and director.
Subscribe to our email newsletter
Previously, Liu served at Irvine – based eGene as founder and CEO and set the company for acquisition by Qiagen in 2007.
He has experience in bio-products development, business development, operational management and sales and marketing.
Pacgen chairman Chung-Yu Wang said Liu’s contributions will assist Pacgen as it creates a new model for the biomedical products, lab testing, and hospital services sectors.
"In combination with our pharmaceutical R&D division, a diversified portfolio will create upside potential and bring more value to the company," Wang said.